Glimartes-M2 SR Tablet is a combination oral antidiabetic medication containing Glimepiride 2 mg and Metformin 500 mg, formulated for sustained release. This dual-action tablet is indicated for the management of type 2 diabetes mellitus in patients whose blood glucose levels are not adequately controlled by diet and exercise alone. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and improving peripheral insulin sensitivity, enhancing glucose uptake by muscle tissues. The sustained-release formulation ensures a gradual release of active ingredients, promoting better glycemic control with reduced gastrointestinal side effects commonly associated with immediate-release metformin. Glimartes-M2 SR is typically prescribed as part of a comprehensive diabetes management plan, including diet modification and regular physical activity. Dosage should be individualized based on patient response and tolerability, with regular monitoring of blood glucose and renal function recommended. Caution is advised in patients with renal impairment, hepatic dysfunction, or conditions predisposing to lactic acidosis. This combination therapy offers an effective approach to achieving optimal glycemic control while minimizing the risk of hypoglycemia and other adverse effects.

Dosage & How to Use